GLP-1 ads flood social media, threaten recovery

Novo Nordisk and Eli Lilly spent $700 million marketing GLP-1 drugs Wegovy, Ozempic, Zepbound, and Mounjaro in the first nine months of 2025. The advertising surge makes weight-loss content inescapable online, triggering disordered eating behaviors in people in recovery. A TikTok algorithm study found users with a history of disordered eating receive more toxic content.